Lannett launches Venlafaxine ER tablets and Lidocaine topical solution 4%
08 January 2020 | News
The estimated IQVIA market values of Venlafaxine ER tablets, 150 mg and 225 mg, USP, and Lidocaine Topical Solution 4% are approximately US$ 150 million and US$ 17 million, respectively, for the 12 months ending November 2019
Lannett Company, Inc. has commenced marketing Venlafaxine Extended Release (ER) Tablets, 150 mg and 225 mg, USP, and Lidocaine Topical Solution 4%.
The estimated IQVIA market values of Venlafaxine ER Tablets, 150 mg and 225 mg, USP, and Lidocaine Topical Solution 4% are approximately $150 million and $17 million, respectively, for the 12 months ending November 2019, although actual generic market values are expected to be lower.
"Both Venlafaxine ER Tablets and Lidocaine Topical Solution 4% are solid additions to our offering and add to our recent wave of product launches," said Tim Crew, chief executive officer of Lannett. "Venlafaxine ER is a partnered product and the Lidocaine Topical Solution 4% is a product we acquired in May 2018 from a subsidiary of Endo International plc."
